Article by Sam Riches, Growth Op
Psychedelic medicine and biotech company MindMed has announced a randomized placebo-controlled study evaluating the benefits of microdosing lysergic acid diethylamide (LSD).
The study will take into account daytime and evening administration of low doses of LSD and its impact on “cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life and immune system response.”
The study will be conducted in collaboration with Dr. Kim Kuypers of Maastricht University in the Netherlands, an associate professor in the faculty of psychology and neuroscience.
Dr. Kuypers’ main goal is “tounderstand the neurobiology underlying flexible cognition, empathy and well-being,” according to her bio at the university.
“I am excited about this new study, which combines a variety of measures ranging from self-reporting and cognitive tasks to health and sleep parameters, bringing us closer to the mechanism of action behind the claimed benefits of microdosing,” she said.
The company will use “digital medicine techniques to expand the measurements enabling us to track and understand cognitive performance, various behavioural variables, productivity and mood indicators,” according to MindMed’s president and head of clinical, Dr. Miri Halperin Wernli.
“We believe that such measurements may offer an efficient way of determining a response loop for better understanding how microdosing can affect the human body,” said Dr. Halperin Wernli.